Astrazeneca Plc, European Union, Astrazeneca Vaccine, Health Authorities, Vaccine, Deep Vein Thrombosis, Pulmonary Embolism, World Health Organisation, Safety Data, Blood Clots, European Medicines Agency

Astrazeneca Plc, European Union

AstraZeneca finds no evidence of increased blood clot risk from vaccine

AstraZeneca Plc said on Sunday a review of safety data of people vaccinated with its COVID-19 vaccine has shown no evidence of an increased risk of blood clots.

15/3/2021 11:29:00 AM

AstraZeneca Plc said on Sunday a review of safety data of people vaccinated with its COVID-19 vaccine has shown no evidence of an increased risk of blood clots .

AstraZeneca's review, which covered more than 17 million people vaccinated in the United Kingdom and European Union , comes after health authorities in some countries suspended the use of its vaccine over clotting issues. 'A careful review of all available safety data of more than 17 million people vaccinated in the European Union and UK with COVID-19 Vaccine AstraZeneca has shown no evidence of an increased risk of pulmonary embolism , deep vein thrombosis or thrombocytopenia, in any defined age group, gender, batch or in any particular country,' the company said.

14 March 2021, 7:35 pm·2-min readFILE PHOTO: Vials labelled"AstraZeneca COVID-19 Coronavirus Vaccine" and a syringe are seen in front of a displayed AstraZeneca logo(Reuters) - AstraZeneca Plc said on Sunday a review of safety data of people vaccinated with its COVID-19 vaccine has shown no evidence of an increased risk of blood clots.

Covid-19: Singapore to put off letting in work pass holders from higher-risk countries it had approved earlier Singapore to extend stay-home notice to 21 days for travellers from higher-risk places Battling COVID-19, and government denial, in rural India

AstraZeneca's review, which covered more than 17 million people vaccinated in the United Kingdom and European Union, comes after health authorities in some countries suspended the use of its vaccine over clotting issues."A careful review of all available safety data of more than 17 million people vaccinated in the European Union and UK with COVID-19 Vaccine AstraZeneca has shown no evidence of an increased risk of pulmonary embolism, deep vein thrombosis or thrombocytopenia, in any defined age group, gender, batch or in any particular country," the company said.

Authorities in Ireland, Denmark, Norway, Iceland and the Netherlands have suspended the use of the vaccine over clotting issues, while Austria stopped using a batch of AstraZeneca shots last week while investigating a death from coagulation disorders. headtopics.com

"It is most regrettable that countries have stopped vaccination on such 'precautionary' grounds: it risks doing real harm to the goal of vaccinating enough people to slow the spread of the virus, and to end the pandemic," Peter English, a retired British government consultant in communicable disease control, told Reuters.

European Medicines Agency has said there is no indication that the events were caused by the vaccination, a view that was echoed by the World Health Organisation on Friday.The drugmaker said, 15 events of deep vein thrombosis and 22 events of pulmonary embolism have been reported so far, which is similar across other licensed COVID-19 vaccines.

The company said additional testing has and is being conducted by the company and the European health authorities and none of the re-tests have shown cause for concern. The monthly safety report will be made public on the EMA website in the following week, AstraZeneca said.

Story continuesThe AstraZeneca vaccine, developed in collaboration with Oxford University, has been authorised for use in the European Union and many countries but not yet by U.S. regulators.The company is preparing to file for U.S. emergency use authorisation and is expecting data from its U.S. Phase III trial to be available in the coming weeks. headtopics.com

Singapore returns to tighter COVID-19 measures: What's allowed under the new rules? India hits 4,000 COVID-19 deaths in a day as cases surge in southern states 'Additional discovery' reviewed as Amos Yee remanded by US court on child porn charges

(Reporting by Radhika Anilkumar and Aakriti Bhalla in Bengaluru, Additional reporting by Kate Kelland in London; Editing by Jane Merriman and Daniel Wallis) Read more: Yahoo Singapore »

Not desirable to move ministers after less than a year, but situation ‘can’t be helped’: PM Lee

SINGAPORE — It is not desirable to give Cabinet ministers short stints in their portfolios owing to the disruption it can cause, but such moves are sometimes necessary, Prime Minister Lee Hsien Loong said on Friday (April 23).